vs
ANI PHARMACEUTICALS INC（ANIP）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.3倍（$324.4M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 5.7%，领先5.4%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 10.4%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $-13.3M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 9.5%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
ANIP vs RVLV — 直观对比
营收规模更大
RVLV
是对方的1.3倍
$247.1M
营收增速更快
ANIP
高出19.2%
10.4%
净利率更高
ANIP
高出5.4%
5.7%
自由现金流更多
ANIP
多$42.4M
$-13.3M
两年增速更快
ANIP
近两年复合增速
9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $324.4M |
| 净利润 | $27.5M | $18.6M |
| 毛利率 | — | 53.3% |
| 营业利润率 | 14.1% | 6.3% |
| 净利率 | 11.1% | 5.7% |
| 营收同比 | 29.6% | 10.4% |
| 净利润同比 | 367.5% | 50.4% |
| 每股收益（稀释后） | $1.14 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRVLV
| Q4 25 | $247.1M | $324.4M | ||
| Q3 25 | $227.8M | $295.6M | ||
| Q2 25 | $211.4M | $309.0M | ||
| Q1 25 | $197.1M | $296.7M | ||
| Q4 24 | $190.6M | $293.7M | ||
| Q3 24 | $148.3M | $283.1M | ||
| Q2 24 | $138.0M | $282.5M | ||
| Q1 24 | $137.4M | $270.6M |
净利润ANIPRVLV
| Q4 25 | $27.5M | $18.6M | ||
| Q3 25 | $26.6M | $21.2M | ||
| Q2 25 | $8.5M | $10.2M | ||
| Q1 25 | $15.7M | $11.8M | ||
| Q4 24 | $-10.3M | $12.3M | ||
| Q3 24 | $-24.2M | $11.0M | ||
| Q2 24 | $-2.3M | $15.4M | ||
| Q1 24 | $18.2M | $10.9M |
毛利率ANIPRVLV
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 54.6% | ||
| Q2 25 | — | 54.1% | ||
| Q1 25 | — | 52.0% | ||
| Q4 24 | — | 52.5% | ||
| Q3 24 | — | 51.2% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 52.3% |
营业利润率ANIPRVLV
| Q4 25 | 14.1% | 6.3% | ||
| Q3 25 | 15.9% | 7.1% | ||
| Q2 25 | 6.6% | 5.8% | ||
| Q1 25 | 13.3% | 5.0% | ||
| Q4 24 | -2.3% | 3.9% | ||
| Q3 24 | -13.8% | 5.0% | ||
| Q2 24 | 3.7% | 5.8% | ||
| Q1 24 | 14.8% | 3.4% |
净利率ANIPRVLV
| Q4 25 | 11.1% | 5.7% | ||
| Q3 25 | 11.7% | 7.2% | ||
| Q2 25 | 4.0% | 3.3% | ||
| Q1 25 | 8.0% | 4.0% | ||
| Q4 24 | -5.4% | 4.2% | ||
| Q3 24 | -16.3% | 3.9% | ||
| Q2 24 | -1.7% | 5.4% | ||
| Q1 24 | 13.2% | 4.0% |
每股收益（稀释后）ANIPRVLV
| Q4 25 | $1.14 | $0.27 | ||
| Q3 25 | $1.13 | $0.29 | ||
| Q2 25 | $0.36 | $0.14 | ||
| Q1 25 | $0.69 | $0.16 | ||
| Q4 24 | $-0.45 | $0.18 | ||
| Q3 24 | $-1.27 | $0.15 | ||
| Q2 24 | $-0.14 | $0.21 | ||
| Q1 24 | $0.82 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $292.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $512.5M |
| 总资产 | $1.4B | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRVLV
| Q4 25 | $285.6M | $292.3M | ||
| Q3 25 | $262.6M | $315.4M | ||
| Q2 25 | $217.8M | $310.7M | ||
| Q1 25 | $149.8M | $300.8M | ||
| Q4 24 | $144.9M | $256.6M | ||
| Q3 24 | $145.0M | $252.8M | ||
| Q2 24 | $240.1M | $244.7M | ||
| Q1 24 | $228.6M | $273.4M |
股东权益ANIPRVLV
| Q4 25 | $540.7M | $512.5M | ||
| Q3 25 | $505.8M | $490.2M | ||
| Q2 25 | $436.8M | $468.6M | ||
| Q1 25 | $418.6M | $453.4M | ||
| Q4 24 | $403.7M | $437.8M | ||
| Q3 24 | $405.9M | $420.8M | ||
| Q2 24 | $455.8M | $405.8M | ||
| Q1 24 | $452.0M | $389.9M |
总资产ANIPRVLV
| Q4 25 | $1.4B | $765.0M | ||
| Q3 25 | $1.4B | $751.3M | ||
| Q2 25 | $1.3B | $722.9M | ||
| Q1 25 | $1.3B | $713.9M | ||
| Q4 24 | $1.3B | $665.5M | ||
| Q3 24 | $1.3B | $670.9M | ||
| Q2 24 | $920.8M | $657.8M | ||
| Q1 24 | $914.5M | $650.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $-13.3M |
| 自由现金流率自由现金流/营收 | 11.8% | -4.1% |
| 资本支出强度资本支出/营收 | 0.5% | 1.0% |
| 现金转化率经营现金流/净利润 | 1.10× | -0.55× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $48.0M |
8季度趋势，按日历期对齐
经营现金流ANIPRVLV
| Q4 25 | $30.4M | $-10.2M | ||
| Q3 25 | $44.1M | $11.8M | ||
| Q2 25 | $75.8M | $12.6M | ||
| Q1 25 | $35.0M | $45.1M | ||
| Q4 24 | $15.9M | $3.9M | ||
| Q3 24 | $12.5M | $9.1M | ||
| Q2 24 | $17.4M | $-24.7M | ||
| Q1 24 | $18.3M | $38.4M |
自由现金流ANIPRVLV
| Q4 25 | $29.1M | $-13.3M | ||
| Q3 25 | $38.0M | $7.5M | ||
| Q2 25 | $71.8M | $10.4M | ||
| Q1 25 | $32.5M | $43.4M | ||
| Q4 24 | $13.5M | $2.1M | ||
| Q3 24 | $7.7M | $8.0M | ||
| Q2 24 | $13.0M | $-25.7M | ||
| Q1 24 | $13.7M | $36.7M |
自由现金流率ANIPRVLV
| Q4 25 | 11.8% | -4.1% | ||
| Q3 25 | 16.7% | 2.5% | ||
| Q2 25 | 34.0% | 3.4% | ||
| Q1 25 | 16.5% | 14.6% | ||
| Q4 24 | 7.1% | 0.7% | ||
| Q3 24 | 5.2% | 2.8% | ||
| Q2 24 | 9.4% | -9.1% | ||
| Q1 24 | 10.0% | 13.5% |
资本支出强度ANIPRVLV
| Q4 25 | 0.5% | 1.0% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 0.7% | ||
| Q1 25 | 1.3% | 0.6% | ||
| Q4 24 | 1.3% | 0.6% | ||
| Q3 24 | 3.2% | 0.4% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.6% |
现金转化率ANIPRVLV
| Q4 25 | 1.10× | -0.55× | ||
| Q3 25 | 1.66× | 0.56× | ||
| Q2 25 | 8.87× | 1.24× | ||
| Q1 25 | 2.23× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | 1.00× | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
